We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

The Age Factor in the Treatment of Glioblastoma

Stephen W. Clark, MD, PhD1,2
[+] Author Affiliations
1Division of Neuro-Oncology, Department of Neurology, Vanderbilt University Medical School, Nashville, Tennessee
2Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
JAMA Neurol. 2016;73(7):783-784. doi:10.1001/jamaneurol.2016.1331.
Text Size: A A A
Published online


The world’s population is aging and rapidly increasing; it is estimated to reach 9.4 billion in 2050, with 1.5 billion people older than 65 years.1 In parallel to an aging population, cancer incidence is expected to rise, and in 2035 it is estimated that 70% of diagnosed cancers in the United States will occur in patients older than 65 years.2 It is logical to assume that this trend will also occur in the primary brain tumor, glioblastoma (GBM). This presents a problem for neuro-oncologists because older patients have been historically underrepresented in neuro-oncology trials. The lack of representation coupled with toxicity concerns often leads to undertreatment in these patients. Given the imminent increasing numbers of elderly patients with GBM, more representation in clinical studies, as well as clear treatment guidelines, is needed for this population.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles